Author Bio
Adria Cimino grew up with her nose in a book and a love of storytelling. By a twist of fate, she started her career writing about biotech in Boston and discovered that each company is the source of many fascinating stories. Prior to joining The Fool as a contract writer focused on healthcare and consumer goods, Adria covered the stock market for Bloomberg News in Paris. When she’s not analyzing companies, she can be found writing fiction or trying to speak French as well as her 9-year-old daughter.
Follow @adria_in_paris
Moderna (NASDAQ:MRNA) has accomplished a lot in the past year. It made a name for itself in the world's most watched space: coronavirus prevention. It launched its first product: a coronavirus vaccine. And last year, it saw its market value and stock price soar -- by more than 500% and 400%, respectively. Those who've been invested in Moderna since Day 1 clearly hit the jackpot.